NeuroPace Inc. Reports FDA Requests More Data on PMA-S for IGE

What Happened

• On July 28, 2026, NeuroPace Inc. announced via press release that the U.S. Food and Drug Administration (FDA) notified the company its Premarket Approval Supplement (PMA-S) to expand the RNS® System label to include patients with antiseizure medication‑resistant idiopathic generalized epilepsy (IGE) with generalized tonic‑clonic (GTC) seizures is "not approvable in its current form."
• The FDA requested additional clinical evidence to support the submission but has invited continued dialogue. NeuroPace said it intends to continue working with the FDA toward a path for approval. The press release is attached to the 8‑K as Exhibit 99.1.

Key Details

• Date of disclosure: July 28, 2026 (press release filed on Form 8‑K).
• Device/Submission: RNS System PMA Supplement to expand indication to medication‑resistant IGE with GTC seizures.
• FDA action: Determined PMA‑S not approvable as submitted and requested additional clinical evidence; invited ongoing discussions.
• Filing: Press release attached as Exhibit 99.1 to the 8‑K.

Why It Matters

• This FDA response delays or complicates NeuroPace’s effort to gain label expansion for the RNS System into the IGE with GTC seizure population, which could have expanded the company’s addressable market if approved.
• The request for more clinical evidence means timing and the nature of any approval are uncertain; investors should note the company did not report any financial impact or change to guidance in this 8‑K.
• Continued engagement with the FDA is positive in that dialogue remains open, but final approval will depend on the additional data the agency requested.